These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 4113388)

  • 1. Viomycin. I. The structure of the guanidine-containing unit.
    Bycroft BW; Croft LR; Johnson AW; Webb T
    J Chem Soc Perkin 1; 1972; 6():820-7. PubMed ID: 4113388
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis of a model relating to the chromophores of capreomycin and viomycin.
    Bycroft BW; Cameron D; Hassanali-Walji A; Johnson AW
    Tetrahedron Lett; 1969 Jun; (30):2539-41. PubMed ID: 4308326
    [No Abstract]   [Full Text] [Related]  

  • 3. The structure, stereochemistry and reactions of the guanidine moiety of viomycin.
    Bycoft BW; Croft LR; Johnson AW; Webb T
    J Antibiot (Tokyo); 1969 Mar; 22(3):133-4. PubMed ID: 4307101
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin.
    McClatchy JK; Kanes W; Davidson PT; Moulding TS
    Tubercle; 1977 Mar; 58(1):29-34. PubMed ID: 68613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to the antibiotics viomycin and capreomycin in the Streptomyces species which produce them.
    Skinner RH; Cundliffe E
    J Gen Microbiol; 1980 Sep; 120(1):95-104. PubMed ID: 6163840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis.
    Tsukamura M; Mizuno S
    J Gen Microbiol; 1975 Jun; 88(2):269-74. PubMed ID: 50402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAPREOMYCIN SUSCEPTIBILITY OF STRAINS RESISTANT TO STREPTOMYCIN AND/OR VIOMYCIN.
    VERBIST L; GYSELEN A
    Am Rev Respir Dis; 1964 Oct; 90():640-1. PubMed ID: 14221679
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACTIVITIES IN BLOOD OF SEVERAL ANTIMYCOBACTERIAL DRUGS DETERMINED BY THE SLIDE CELL CULTURE METHOD AS COMPARED WITH IN VITRO ACTIVITIES. I. CONCERNING STREPTOMYCIN, KANAMYCIN, CAPREOMYCIN AND VIOMYCIN].
    NAGATA A; MATSUMOTO M; MASE M
    Kekkaku; 1965 Jan; 40():6-11. PubMed ID: 14288531
    [No Abstract]   [Full Text] [Related]  

  • 10. Semisynthesis of di-beta-lysylcapreomycin IIA, a capreomycin analog effective against viomycin-resistant Mycobacterium.
    Wakamiya T; Shiba T
    J Antibiot (Tokyo); 1983 Feb; 36(2):197-9. PubMed ID: 6187721
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antituberculous activity of capreomycin and cross resistance to kanamycin, capreomycin, and viomycin. 2. In vitro study of cross resistance to capreomycin, kanamycin and viomycin].
    Tanaka K; Saiga S
    Bull Chest Dis Res Inst Kyoto Univ; 1969 Sep; 3(1):44-51. PubMed ID: 5401219
    [No Abstract]   [Full Text] [Related]  

  • 12. The structure of the guanido amino acid moiety of viomycin.
    Takita T; Maeda K
    J Antibiot (Tokyo); 1968 Aug; 21(8):512-6. PubMed ID: 4303539
    [No Abstract]   [Full Text] [Related]  

  • 13. [The degree of cross-resistance to kanamycin (KM) of tubercle bacilli resistant to capreomycin (CPM), and the degree of cross-resistance to KM and CPM of tubercle bacilli resistant to viomycin (VM) (author's transl)].
    Inagake H; Yamadori H; Inoue N; Mabuchi H; Ikeda N; Maekawa N
    Kekkaku; 1980 Jul; 55(7):323-30. PubMed ID: 6162994
    [No Abstract]   [Full Text] [Related]  

  • 14. The ototoxic interaction of viomycin, capreomycin and polymyxin B with ethacrynic acid.
    Davis RR; Brummett RE; Bendrick TW; Himes DL
    Acta Otolaryngol; 1982; 93(1-6):211-7. PubMed ID: 6175163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of co-resistance to streptomycin, kanamycin, capreomycin, and tuberactinomycin in core particles derived from ribosomes of viomycin-resistant Mycobacterium smegmatis.
    Yamada T; Mizuguchi Y; Suga K
    J Antibiot (Tokyo); 1976 Oct; 29(10):1124-6. PubMed ID: 62857
    [No Abstract]   [Full Text] [Related]  

  • 16. CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. II. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF ETHAMBUTOL, CAPREOMYCIN AND COMPANION DRUGS, INCLUDING 4-4 DIISOAMYLOXYTHIOSEMICARBANILIDE.
    KASS I
    Tubercle; 1965 Jun; 46():166-77. PubMed ID: 14327964
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of kanamycin, viomycin and capreomycin resistance of Mycobacterium tuberculosis].
    Tomoda T; Minami Y; Maekawa Y; Oi Y
    Rinsho Byori; 1971 Jun; 19(6):423-6. PubMed ID: 4111341
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101,680 and CP-163,234, for animal health use.
    Norcia LJ; Silvia AM; Dirlam JP; Schnur RC; Bergeron JM; Retsema JA; Hayashi SF
    J Antibiot (Tokyo); 1999 Nov; 52(11):1007-16. PubMed ID: 10656573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viomycin. II. The structure of the chromophore.
    Bycroft BW; Cameron D; Croft LR; Hassanali-Walji A; Johnson AW; Webb T
    J Chem Soc Perkin 1; 1972; 6():827-34. PubMed ID: 4338113
    [No Abstract]   [Full Text] [Related]  

  • 20. Viomycin. Further degradative studies.
    Bycroft BW; Cameron D; Croft LR; Johnson AW; Webb T; Coggon P
    Tetrahedron Lett; 1968 May; (25):2925-30. PubMed ID: 4297159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.